(1) Long molecules of DNA are labeled with Bionano reagents by (2) incorporation of fluorophores at a specific sequence motif throughout the genome. (3) The labeled genomic DNA is then linearized in the Saphyr Chip using NanoChannel arrays (4) Single molecules are imaged by Saphyr and then digitized. (5) Molecules are uniquely identifiable by distinct distribution of sequence motif labels (6) and then assembled by pairwise alignment into de novo genome maps.
In cancer genetics, the ability to identify constitutive and low-allelic fraction structural variants (SVs) is crucial. Conventional karyotype and cytogenetics approaches are manually intensive. Microarrays and shortread sequencing cannot detect calls in segmental duplications and repeats, often miss balanced variants, and have trouble finding lowfrequency mutations. We describe the use of Bionano Genomics' Saphyr platform to comprehensively identify SVs for studying cancer genomes. DNA larger than 100 kbp are extracted, labelled at specific motifs, and linearized through NanoChannel arrays for visualization. Molecule images are digitized and de novo assembled, creating megabases long Bionano genome maps. Somatic mutations can be identified by running the variant annotation pipeline, which compares the cancer sample's assembly calls against > 600,000 SVs in Bionano's control sample SV database, and against a matched control sample's variants. In addition, two new Bionano pipelines leverage these long molecules to identify additional somatic SVs: the copy number variation pipeline and the molecule mapping pipeline. By examining the coverage-depth of molecule alignment to the public human genome reference, the pipeline can identify megabases long amplifications and deletions. Similarly, clusters of split-molecule alignments against a reference can reliably find translocations and other rearrangements. We applied this suite of discovery tools to construct a comprehensive map of SVs in a well-studied melanoma cell line, COLO829. We collected data from the tumor and the matched blood cell line, constructed contiguous assemblies (N50 > 50 Mbp), and called over 6,000 SVs in each genome. Then, we classified 51 as somatic by comparing the tumor and the blood control. Furthermore molecule mapping identified extra mutations. The copy number profile captured the BRAF on chr7, as well as other chromosomal-arm gains and losses. In conclusion, with one comprehensive platform, Saphyr can discover a broad range of traditionally refractory but functionally-relevant SVs, and further improves our understanding of cancer etiology.
Generating high-quality finished genomes replete with accurate identification of structural variation and high completion (minimal gaps) remains challenging using short read sequencing technologies alone. The Saphyr™ system provides direct visualization of long DNA molecules in their native state, bypassing the statistical inference needed to align paired-end reads with an uncertain insert size distribution. These long labeled molecules are de novo assembled into physical maps spanning the entire diploid genome. The resulting provides the ability to correctly position and orient sequence contigs into chromosome-scale scaffolds and detect a large range of homozygous and heterozygous structural variation with very high efficiency. 
